<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-355-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOXORUBICIN 2MG-MLVIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOXORUBICIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        105.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your medicine contains the active ingredient doxorubicin. Doxorubicin belongs to a group of anti-tumour drugs (anti-cancer drugs) called anthracyclines. Doxorubicin destroys tumour (cancer) cells and ensures that they can no longer grow.</p><p>&nbsp;</p><p>Doxorubicin Ebewe is used in the treatment of</p><p>&middot; Breast cancer</p><p>&middot; &nbsp;Bone cancer (osteosarcoma, Ewings sarcoma), administered before as well as after surgery</p><p>&middot; Soft tissue cancer (advanced soft tissue sarcoma in adults)</p><p>&middot; Lung cancer (small cell lung carcinoma)</p><p>&middot; Lymph tissue cancer (Hodgkin and non-Hodgkin lymphoma)</p><p>&middot; Certain types of blood cancer (acute lymphatic or myeloblastic leukaemia)</p><p>&middot; Bone marrow cancer (multiple myeloma)</p><p>&middot; Endometrium cancer (advanced or recurring</p><p>endometrium carcinoma)</p><p>&middot; &nbsp;Thyroid cancer (advanced papillary / follicular thyroid cancer, anaplastic thyroid cancer)</p><p>&middot; &nbsp;Certain types of bladder cancer (spreading at a localised or advanced stage) For early (superficial) bladder cancer, the medicine is also administered intravesically (inside the bladder) to prevent a recurrence of bladder cancer after surgery.</p><p>&middot; Recurring ovarian cancer</p><p>&middot; Kidney cancer occurring at a certain age in children (Wilms tumour)</p><p>&middot; Nerve tissue cancer occurring in childhood (advanced neuroblastoma)</p><p>&nbsp;</p><p>Doxorubicin is also used in combination with other anti-cancer drugs.</p><p>&nbsp;</p><p>As doxorubicin is an anti-cancer drug, you will receive treatment in a specialist department and under the supervision of a doctor qualified in the use of anti-cancer drugs. The department staff will explain to you the things you will have to pay special attention to during and after treatment. These instructions may serve you as a reminder.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Doxorubicin Ebewe must not be administered if</strong></p><p>&middot; You are allergic to doxorubicin or any of the other ingredients of this medicine listed in section 6 or other medicinal products belonging to the same group of drugs (so-called anthracyclines or anthracenediones)</p><p>&middot; During pregnancy or your lactation period</p><p>&nbsp;</p><p>Depending on the type of administration, Doxorubicin Ebewe MUST NOT be given to you</p><p>in the following situations:</p><p>&nbsp;</p><p><strong>Intravenous administration (into a vein):</strong></p><p>&middot; If your blood cell production has decreased, your bone marrow function is reduced (myelosuppression) or your oral mucosa are inflamed (stomatitis) due to previous treatment with anti-cancer drugs or radiation.</p><p>&middot; &nbsp;If you are or were suffering from cardiac disorders (angina pectoris [Tightness in the chest], myocardial insufficiency, severe cardiac arrhythmia and conduction disturbance, acute inflammatory cardiac disorder, cardiac infarction during the last 6 months, disorders of the heart muscle)</p><p>&middot; If your liver function is severely impaired</p><p>&middot; If you have previously been treated with the maximum dose of similar anti-cancer drugs (other anthracyclines such as epirubicin, idarubicin or daunorubicin)</p><p>&middot; If you suffer from an acute infection</p><p>&middot; If you are bleeding more easily</p><p>&middot; If your suffer from inflammation of the oral mucosa</p><p>&middot; If you are breast feeding</p><p>&nbsp;</p><p><strong>Intravesical administration (into the bladder):</strong></p><p>&middot; If the cancer has spread into the bladder wall</p><p>&middot; If you suffer from a urinary tract infection</p><p>&middot; If you suffer from a bladder infection</p><p>&middot; If your urine cannot be discharged through a catheter (a tube inserted in the bladder for discharging urine)</p><p>&middot; If there is blood in your urine (haematuria)</p><p>&middot; If you are breast feeding</p><p>&nbsp;</p><p><strong>Warnings and precautions for use</strong></p><p>Please talk to your doctor, pharmacist or trained medical staff before being given</p><p>Doxorubicin Ebewe.</p><p>&nbsp;</p><p><strong>Your doctor will supervise your treatment with Doxorubicin Ebewe closely</strong></p><p>&middot; If you are an elderly patient</p><p>&middot; If you have a history of heart disease</p><p>&middot; If you have a history of bone marrow suppression</p><p>&middot; If you previously received radiation therapy on the chest (mediastinum)</p><p>&nbsp;</p><p>&middot; If you were previously treated with similar anti-cancer drugs (other anthracyclines)</p><p>&nbsp;</p><p>Important information on Doxorubicin Ebewe:</p><p>&middot; Doxorubicin may cause potentially permanent infertility in both men and women.</p><p>&middot; &nbsp;If you experience a stinging or burning sensation at the point of the doxorubicin injection, this may be caused by the drug leaking from the vein (extravasation). Inform your doctor immediately in such case. He or she will use another vein for your treatment and carefully monitor the area affected by the leak.</p><p>&middot; If you previously received treatment with doxorubicin (up to 20 years in the past) and become pregnant, your doctor will monitor your heart, even if you did not have any heart problems in the past</p><p>&middot; Your urine may take on a red colour during treatment with doxorubicin.</p><p>&middot; &nbsp;During treatment with doxorubicin, you may experience severe discomfort such as nausea, vomiting and inflammations of the oral and nasal mucosa. Please inform your doctor immediately if you experience any of the above; he will give you the necessary treatment.</p><p>&middot; It is recommended not to have any vaccinations during treatment with doxorubicin. You should also avoid contact with persons who were recently vaccinated against polio.</p><p>&nbsp;</p><p><strong>Before and during treatment with Doxorubicin Ebewe, your doctor will</strong></p><p>&middot; Check your blood count, as treatment with doxorubicin may damage your bone marrow, which would reduce the number of your white blood cells and make you more susceptible to infections and bleeding. Your doctor may reduce, stop or delay treatment if he detects severe bone marrow depression.</p><p>&middot; Check your lungs and chest to ensure that your lungs function properly during treatment.</p><p>&middot; &nbsp;Perform an electrocardiogram (ECG) to record your cardiac activity, as doxorubicin may cause an inflammation of the heart muscle (cardiomyopathy). This may occur, in particular, if you have a history of cardiac disorder, are over 70 or under 15, have previously been treated with doxorubicin (or other similar anthracyclines) or received radiotherapy of the chest cavity. A total (cumulative) dose of 450 &ndash; 550 mg/m2 must not be exceeded as higher doses severely increase the risk of developing heart failure, especially in children and patients with a history of heart disease. The maximum dose for children is usually regarded as 300 mg/m2 (for children under 12 years of age) and up to 450 mg/m2 (for children over 12 years of age). The total maximum dose may be even lower for infants. Your doctor may also carry out other tests for monitoring your heart function (e.g. echocardiography or radionuclide angiography] MUGA Scan]).</p><p>&middot; Monitor the uric acid level in your blood to ensure that you are supplied with sufficient liquid as doxorubicin may increase the uric acid levels in your blood (hyperuricemia). Please inform your doctor if you notice any joint pain or symptoms of gout.</p><p>&middot; &nbsp;Regularly examine your mouth and throat as doxorubicin may cause changes in the mucosa in your mouth and throat</p><p>&middot; Monitor your renal function. It may be necessary to reduce the dose.</p><p>&middot; Monitor your liver function (blood tests). The dose may have to be reduced if your liver function is impaired. If you suffered from hepatitis B or C in the past, treatment with doxorubicin may reactivate this disease.</p><p>&nbsp;</p><p>&middot; Check your general state of health, as doxorubicin must not be administered if you have any inflammations, ulcers or diarrhoea. Your doctor will treat you for any infections before administering doxorubicin.</p><p>&nbsp;</p><p><strong>Using Doxorubicin Ebewe in combination with other drugs</strong></p><p>Please inform your doctor or pharmacists if you are taking / using, have recently taken / used or are planning to take / use other drugs.</p><p>&nbsp;</p><p>Please inform your doctor immediately if you</p><p>&middot; &nbsp;Are simultaneously being given other cancer drugs such as anthracyclines (daunorubicin, epirubicin, idarubicin), cisplatin, cyclophosphamide, ciclosporin, cytarabine, dacarbazine, dactinomycin, 5-fluorouracil, mitomycin C and taxanes, as they may damage your heart. The administration of doxorubicin in combination with cytarabine may also damage the colon.</p><p>&middot; Are simultaneously taking drugs that impact your cardiac function (such as calcium antagonists, verapamil).</p><p>&middot; Were previously or will shortly be treated with trastuzumab (anti-cancer drug), as it may be necessary for your doctor to monitor your heart function.</p><p>&middot; Are being or were previously treated with paclitaxel (anti-cancer drug), as this may increase the effects and side effects of doxorubicin.</p><p>&middot; Are taking barbiturates (certain sleeping pills) or rifampicin (antibiotic), as the volume of doxorubicin in the blood may drop in this case, which would reduce the effectiveness of doxorubicin.</p><p>&middot; &nbsp;Have previously been treated with 6-mercaptopurine, methotrexate or streptozocin (cancer drug), as this increases the risk of side effects on the liver.</p><p>&middot; &nbsp;Are being treated with drugs that have an impact on bone marrow, such as sulphonamides (for infections), chloramphenicol, (for infections), phenytoin (for epilepsy), amidopyrine derivatives (for pain and inflammations) and antiretroviral drugs (for AIDS, e.g. ritonavir). This may lead to bone marrow suppression and reduce the number of blood cells.</p><p>&middot; Are taking ciclosporine (to suppress your natural immunity) or cimetidine (for stomach ulcers), as this may increase the level of doxorubicin in the blood. Your doctor may consider reducing the dose.</p><p>&middot; Are, have been, or will be receiving radiotherapy, as this may increase the occurrence of side effects.</p><p>&middot; Previously took cyclophosphamide (anti-cancer drug), as this increases the risk of side effects on the bladder (haemorrhaging cystitis, a bladder infection that sometimes causes blood in the urine).</p><p>&middot; Are taking drugs for the reduction of uric acid. The doses of these drugs may have to be adjusted as doxorubicin may increase the uric acid level in the blood.</p><p>&middot; Are taking digoxin (for the heart), as the effectiveness of digoxin may be reduced.</p><p>&middot; Are taking drugs used in the treatment of epilepsy such as phenytoin, carbamazepine and valproate, as the effect of these drugs may be reduced.</p><p>&middot; Are being simultaneously treated with progesterone (corpus luteum hormone).</p><p>&middot; Are being given clozapine (drug for the treatment of psychosis).</p><p>&middot; Are also being treated with heparin (to avoid blood clotting) or 5- fluorouracil (anti-cancer drug). If administered in the same infusion, doxorubicin may bind them and cause them to become ineffective.</p><p>&middot; Are being treated with amphotericin B, a drug for fungal infections.</p><p>&middot; Are taking diuretics or antidiabetics (e.g. sulphonamide).</p><p>&middot; Are due to have a vaccination.</p><p>&nbsp;</p><p><strong>Pregnancy, lactation and fertility</strong></p><p>Please seek advice from your doctor or pharmacist prior to taking this drug if you are, expecting that you may be, or planning to become pregnant or if you are breast feeding.</p><p>&nbsp;</p><p>Doxorubicin Ebewe must not be administered during pregnancy and lactation. Women should avoid becoming pregnant during treatment with doxorubicin and up to 6</p><p>months thereafter as damage to the child cannot be ruled out. You must use effective contraception during and up to 6 months after treatment.</p><p>&nbsp;</p><p>Men should use suitable contraception during treatment with doxorubicin and up to 6 months thereafter, as the genetic makeup may be damaged and to ensure that their partners will not get pregnant during this period.</p><p>Please consult your doctor if you are considering fathering a child after treatment. As doxorubicin may cause irreversible infertility, it is recommended to discuss the option of cryogenically freezing your sperm (cryopreservation) prior to treatment with your doctor.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_17" o:spid="_x0000_s2050" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:84.05pt;
 margin-top:12.65pt;width:25.5pt;height:23.25pt;z-index:-251660800;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="34" height="31" src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><strong>Driving vehicles and operating machinery</strong></p><p>Warning: This drug may affect your reactions and ability to drive a vehicle.</p><p>&nbsp;</p><p>Due to the regular occurrence of nausea and vomiting, it is recommended that you do not</p><p>steer any vehicles or operate machinery.</p><p>&nbsp;</p><p><strong>Doxorubicin Ebewe contains sodium</strong></p><p>This medicinal product contains approximately 133.8 mg sodium per m2 body surface area (BSA). This should be taken into account if you are on a low-sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A doctor will treat you with Doxorubicin Ebewe. Your doctor may carry out some tests, such as blood tests and ECGs, before or during treatment with Doxorubicin Ebewe to decide on the correct dose for you.</p><p>&nbsp;</p><p>Doxorubicin Ebewe is administered into one of your veins through an intravenous (i.v.) infusion</p><p>(intravenous administration) or your bladder (intravesical administration).</p><p>&nbsp;</p><p>Preparations and administration must be carried out by trained medical staff at a hospital.</p><p>&nbsp;</p><p>The dose will depend on your age (lower doses may be required for children and elderly patients), weight and general state of health. It will also depend on all other cancer treatments you may have previously been given. Your doctor will calculate your body surface area in square metres (m2). You will receive the drug every 3 weeks for a period of 6 to 12 months. Administration into the bladder may be repeated at intervals of 1 week to 1 month. The exact length of your treatment will depend on your state of health.</p><p>&nbsp;</p><p><strong>Patients with kidney or liver disease</strong></p><p>It may be necessary to reduce the dose of your liver function is impaired or your renal function is severely impaired.</p><p>&nbsp;</p><p>You must not be given Doxorubicin Ebewe if your liver function is severely impaired.</p><p>&nbsp;</p><p><strong>If the planned dose of Doxorubicin Ebewe has been exceeded </strong></p><p>As the drug will be administered by a doctor, it is unlikely that you will receive an overdose. However, if you are in doubt, please inform your doctor or trained medical staff <strong><u>immediately</u></strong>.</p><p>&nbsp;</p><p>You may experience side effects on your gastrointestinal tract (particularly inflammation of the mucosa) and heart within 24 hours after receiving a single high dose of doxorubicin. Severe bone marrow suppression (myelosuppression) may also occur after 10 to 14 days. This may be accompanied by an increased risk of bleeding and the occurrence of bruising (thrombocytopenia) as well as an increased risk of infection (from leukopenia).</p><p>&nbsp;</p><p>Treatment will take place in a hospital and include administration of antibiotics (drugs for infections), blood transfusions (particularly white blood cells and platelets) and treatment of the side effects on the gastrointestinal</p><p>tract and the heart. You may be transferred to a sterile room. Should you experience side effects on the heart, you should be examined by a cardiologist.</p><p>&nbsp;</p><p>Accidental administration outside the vein (extravasation) may cause severe localised side effects, including tissue death (necrosis) and inflammation of the vein with blood clotting (thrombophlebitis). A burning sensation in the area of the infusion&#39;s point of administration may be a sign thereof and you must alert your doctor<strong><u> immediately</u> </strong>if you suspect this to have happened.</p><p>&nbsp;</p><p>Note to the doctor: For information on overdoses, please refer to the end of the leaflet.</p><p>&nbsp;</p><p>Please contact your doctor or pharmacist if you have any further questions regarding the use of this drug.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all drug, this drug may have side effects that may not, however, manifest themselves in all patients.</p><p>&nbsp;</p><p>Please inform your doctor immediately if you experience one of the following:</p><p>&middot; An allergic reaction causing the swelling of lips, face or neck, in turn leading to severe respiratory distress, skin rash or hives (angioneurotic oedema) or anaphylactic shock (severe drop in blood pressure, paleness, agitation, weak pulse, impaired consciousness)</p><p>&middot; Severe discomfort such as nausea, vomiting and inflammations of the oral and nasal mucosa</p><p>&nbsp;</p><p>You may require urgent medical assistance.</p><p>&nbsp;</p><p>Some of the side effects may be extremely severe and require careful patient monitoring. Some of the side effects depend on the speed of administration as well as type of dosing. Bone marrow suppression is one such example and may be extremely severe despite usually being of a temporary nature. Common symptoms of bone marrow damage re fever, infections, blood poisoning (sepsis, meaning</p><p>&nbsp;</p><p>bacteria in the blood due to a suppression of the immune system), shock as a result of blood poisoning (septic shock with severe drop in blood pressure, paleness, agitation, weak and fast pulse, sweaty skin, loss of consciousness), bleeding, oxygen starvation in the tissue (tissue hypoxia) and necrosis.</p><p>&nbsp;</p><p>Accidental administration outside the vein (extravasation) may cause severe skin inflammation (cell inflammation), blistering, inflammation of the vein with blood clotting (thrombophlebitis), inflammation of the lymph vessels (lymphangitis), characterised by painful subcutaneous red stripy marks, and localised cell necrosis that may require surgery (including skin transplants).</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_8" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:78.4pt;margin-top:37.9pt;width:445.75pt;height:94.4pt;
 z-index:-251659776;mso-position-horizontal-relative:page' coordorigin="1568,758"
 coordsize="8915,1888" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:group id="Group_x0020_15" o:spid="_x0000_s1027" style='position:absolute;
  left:1578;top:768;width:2;height:1868' coordorigin="1578,768" coordsize="2,1868"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_16" o:spid="_x0000_s1028" style='position:absolute;
   left:1578;top:768;width:2;height:1868;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDSV7/7xAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
EIXvBf/DMoK3urEHKdFVilrwIJSmij0Ou9MkNDsbs2uS/vvOodDbDO/Ne9+st6NvVE9drAMbWMwz
UMQ2uJpLA+eP18dnUDEhO2wCk4EfirDdTB7WmLsw8Dv1RSqVhHDM0UCVUptrHW1FHuM8tMSifYXO
Y5K1K7XrcJBw3+inLFtqjzVLQ4Ut7Sqy38XdGzh9xludxuuwL6ylxeH4drn22pjZdHxZgUo0pn/z
3/XRCb7Qyy8ygN78AgAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhANJXv/vEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,l,1868e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,768;0,2636"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_13" o:spid="_x0000_s1029"
  style='position:absolute;left:10473;top:768;width:2;height:1868'
  coordorigin="10473,768" coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_14" o:spid="_x0000_s1030" style='position:absolute;
   left:10473;top:768;width:2;height:1868;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l,1868e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,768;0,2636"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_11" o:spid="_x0000_s1031"
  style='position:absolute;left:1573;top:763;width:8905;height:2'
  coordorigin="1573,763" coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_12" o:spid="_x0000_s1032" style='position:absolute;
   left:1573;top:763;width:8905;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l8905,e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;8905,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_9" o:spid="_x0000_s1033"
  style='position:absolute;left:1573;top:2641;width:8905;height:2'
  coordorigin="1573,2641" coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD9SmGCwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Na8JA
EL0X/A/LCL3VTVpSSnQNQaz0EIRqQbwN2TEJZmdDdk3iv+8Khd7m8T5nlU2mFQP1rrGsIF5EIIhL
qxuuFPwcP18+QDiPrLG1TAru5CBbz55WmGo78jcNB1+JEMIuRQW1910qpStrMugWtiMO3MX2Bn2A
fSV1j2MIN618jaJ3abDh0FBjR5uayuvhZhTsRhzzt3g7FNfL5n4+JvtTEZNSz/MpX4LwNPl/8Z/7
S4f5CTx+CQfI9S8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA/UphgsMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
">
  <v:shape id="Freeform_x0020_10" o:spid="_x0000_s1034" style='position:absolute;
   left:1573;top:2641;width:8905;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l8905,e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;8905,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]-->The following side effects were reported at these approximate frequencies:</p><p>&nbsp;&nbsp;&nbsp;&nbsp; Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects more than 1 in 10 patients</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects up to 1 in 10 patients</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects up to 1 in 100 patients</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects up to 1 in 1,000 patients</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; affects up to 1 in 10,000 patients</p><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequency cannot be estimated form the available data</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Very common</u></p><p>&middot; Infections</p><p>&middot; Nausea, vomiting, diarrhoea</p><p>&middot; Hair loss (alopecia, depending on dose, hair grows again in most cases)</p><p>&middot; Red colouration of the urine (1 &ndash; 2 days after treatment with doxorubicin)</p><p>&middot; Bone marrow suppression (myelosuppression), including a reduction of the number of white blood cells (leukopenia) and platelets (thrombocytopenia), and a reduction of the neutrophile white blood cells (neutropenia), which may also be accompanied by fever (febrile neutropenia)</p><p>&middot; Severe general changes of the blood count (pancytopenia)</p><p>&middot; Lack of oxygen in the tissue or tissue necrosis</p><p>&middot; Anaemia (reduction of red blood cells, which may result in pale skin and weakness or breathlessness)</p><p>&middot; Loss of appetite (anorexia)</p><p>&middot; Heart muscle damage (cardiotoxicity). The risk increases in patients treated with radiation therapy or other cardiotoxic drugs, in patients over 70 or under 15 and patients suffering from additional conditions such as anaemia, pericarditis and myocarditis. Such effects may occur shortly after starting treatment or several years thereafter.</p><p>&middot; Inflammation of the nasal, oral or vaginal mucosa (mucositis)</p><p>&middot; Inflammation or ulceration of the mucosa in the mouth (stomatitis) or oesophagus (oesophagitis)</p><p>&middot; Hypersensitivity of the skin to artificial and natural light (photosensitivity), reddening of the skin (erythema), skin rash (exanthema) and local symptoms of poisoning (local toxicity)</p><p>&middot; Detachment of the nails (onycholysis)</p><p>&middot; Fever, chills</p><p>&middot; Weakness / loss of energy</p><p>&middot; Inflammation of the veins with blood clotting (thrombophlebitis)</p><p>&nbsp;</p><p>&middot; Abnormal result of certain heart examinations (asymptomatic reduction of the LVEF), abnormal electrocardiogram (ECG), abnormal liver values (transaminase), weight gain</p><p>&nbsp;</p><p><u>Common</u></p><p>&middot; Blood poisoning (sepsis), blood poisoning with infectious inflammation (septicaemia)</p><p>&middot; Dehydration</p><p>&middot; Conjunctivitis</p><p>&middot; Arrhythmia (irregular, accelerated or slower heart beat), reduction of the volume of blood pumped through the left heart chamber into the body, potentially fatal impairment of the heart muscle (cardiomyopathy)</p><p>&middot; Bleeding (haemorrhage)</p><p>&middot; Inflammation of the veins (phlebitis)</p><p>&middot; Abdominal pain or burning sensation</p><p>&middot; Inflammatory reactions in areas previously treated with radiation therapy (so-called radiation recall reaction)</p><p>&middot; Itching</p><p>&middot; Hyperpigmentation of skin and nails</p><p>&middot; Urticaria</p><p>&middot; Reactions at the point of injection, including reddening of the skin along the vein, inflammation of the veins (phlebitis), thickening or hardening of the vascular walls (phlebosclerosis)</p><p>&nbsp;</p><p>The following common side effects may occur after administration into the bladder:</p><p>&middot; Inflammation of the bladder</p><p>&middot; Unpleasant, difficult or painful urination (dysuria)</p><p>&middot; Irritation of the bladder or urinary tract</p><p>&middot; Urge to urinate during the night (nocturia)</p><p>&middot; Increased urination (polyuria)</p><p>&middot; Painful urge to urinate (stranguria)</p><p>&middot; Frequent voiding of small quantities of urine (pollakisuria)</p><p>&middot; Blood in the urine (haematuria)</p><p>&middot; Bladder cramps</p><p>&middot; Tissue necrosis</p><p>&middot; Bladder inflammation causing blood in the urine (haemorrhaging cystitis)</p><p>&nbsp;</p><p><u>Uncommon</u></p><p>&middot; Blood poisoning with shock-like states (septic shock)</p><p>&middot; Doxorubicin may cause certain types of blood cancer (leukaemia), also in combination with other cancer drugs. These forms of cancer show their symptoms within 1 to 7 years.</p><p>&middot; Blockage of a blood vessel through blood clotting (thromboembolism)</p><p>&middot; Bleeding in the stomach or intestine, inflammation of the intestine and stomach mucosa, tissue necrosis in the colon with massive bleeding and severe infections if doxorubicin is administered in combination with cytarabine (a cancer drug).</p><p>&nbsp;</p><p><u>Rare</u></p><p>&middot; Dizziness</p><p>&middot; Swelling (angio oedema) of the eye lids and tongue with impaired breathing</p><p>&middot; Shock</p><p>&middot; Impaired breathing, swelling of the nasal mucosa, rapid and difficult breathing, pneumonia caused by radiotherapy</p><p>&nbsp;</p><p>&middot; Accidental administration outside the vein (extravasation), which may cause severe inflammation of the subcutaneous tissue and the blood and lymph vessels, blistering and local tissue necrosis</p><p>&nbsp;</p><p><u>Very rare</u></p><p>&middot; Allergic reaction causing respiratory distress or dizziness (anaphylaxia)</p><p>&middot; Cardiac arrhythmia (non-specific ECG changes)</p><p>&middot; Isolated cases of potentially fatal irregular heartbeat (arrhythmia), left ventricular heart failure, inflammation of the pericardial sac surrounding the heart that causes chest pain and fluid retention around the heart (pericarditis), inflammation of the heart muscle and the pericardial sac (pericarditis-myocarditis syndrome), loss of nerve impulses in the heart (atrioventricular block, bundle-branch block)</p><p>&middot; Ulcers in the mucosa of the mouth, throat, oesophagus, stomach or intestine, discolouration (hyperpigmentation) of the oral mucosa</p><p>&middot; Swelling and numbness of hands and feet (acral erythema)</p><p>&middot; Tissue damage, particularly on hands and feet, leading to reddening, swelling, blistering, tingling or a burning sensation caused by the leaking of the drug into the tissue (erythrodysaesthesia, hand and foot syndrome)</p><p>&middot; General muscle weakness</p><p>&middot; Acute renal failure (isolated cases)</p><p>&middot; Increased uric acid levels in the blood (hyperuricaemia) caused by the rapid dissolution of a tumour that may cause gout, kidney stones or kidney damage</p><p>&middot; General malaise</p><p>&nbsp;</p><p><u>Not known</u></p><p>&middot; Erratic metabolism caused by the rapid dissolution of tumour cells (tumour lysis syndrome)</p><p>&middot; Hot flashes</p><p>&middot; Breathlessness due to cramps in the muscles of the respiratory tract (bronchospasms)</p><p>&middot; Temporary increase in liver enzyme levels</p><p>&middot; Severe liver damage, which may progress into permanent damage of the liver tissue (cirrhosis) in some cases</p><p>&middot; Inflammation of the cornea (ceratitis), increased tear flow</p><p>&middot; Severe pain and swelling of the joints (arthralgia)</p><p>&middot; Radiation damage (of the skin, lungs, oesophagus, gastrointestinal mucosa, heart) that is healing may recur after treatment with doxorubicin</p><p>&middot; Thick, scaly or crusty patches on the skin (actinic keratosis)</p><p>&middot; No menstruation (amenorrhea)</p><p>&middot; Impaired fertility in men (reduction or lack of active sperm)</p><p>&nbsp;</p><p><strong>Reporting side effects</strong></p><p>If you notice any side effects, you should contact your doctor, pharmacist or trained medical staff. This includes side effects that are not listed in this leaflet.</p><p>By reporting side effects, you can help increase the information on the safety of this drug.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>Store medicinal product in the original packaging in order to protect the contents from light.</p><p>&nbsp;</p><p>Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours at controlled room temperature (15&deg; to 25&deg;C).</p><p>&nbsp;</p><p>For single use only. Discard any surplus. Keep this drug out of the reach of children.</p><p>Do not use this medicine after the &quot;expiry date&quot; shown on the outer carton and</p><p>label. The expiry date refers to the last day of the month.</p><p>&nbsp;</p><p>Any remaining medicine and primary packaging must be disposed of as hazardous waste.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Doxorubicin is the active ingredient.</p><p>1 ml concentrate for the preparation of an infusion solution contains 2 mg doxorubicin in the form of doxorubicin hydrochloride.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: Sodium chloride, hydrochloric acid solution for adjusting the pH value, water for injection purposes</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, red solution.
Vials made from Ph.Eur. type I glass with grey Teflon-coated chlorobutyl rubber stopper and aluminium cap, packaged in a carton.

Pack sizes:
1 x 5 ml vial
5 x 5 ml vial
10 x 5 ml vial
1 x 25 ml vial
1 x 50 ml vial
1 x 100 ml vial
Glass vials with/without clear plastic container (ONKO-Safe). Not all packaging sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBEWE Pharma Ges.m.b.H. Nfg. KG, 4866 Unterach, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواؤك على المادة الفعَّالة دوكسوروبيسين. ينتمي دوكسوروبيسين إلى مجموعة من العقاقير المضادة للأورام (عقاقير مضادة للسرطان) تسمى أنْثراسيكلينات. ويعمل دوكسوروبيسين على تدمير خلايا الورم (السرطان) وتضمن عدم قدرتها على النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار دوكسوروبيسين إيبيفيه في علاج الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان العظام (الساركومة العظمية، ساركومة إوينج)، يُؤخذ قبل الجراحة وبعدها كذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الأنسجة الرَّخوة (ساركومة الأنسجة الرَّخوة المتقدمة لدى البالغين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الرئة (سرطان الخلايا الصغيرة الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الأنسجة الليمفاوية (سرطان الغدد الليمفاوية الهودجكين وغير الهودجكين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من سرطان الدَّم (سرطان الدَّم النخاعي الحاد أو الليمفاوي الحاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان النخاع العظمي (الورم النقوي المتعدد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان بطانة الرحم (سرطان بطانة الرَّحم المتقدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو المُعاوِد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدة الدَّرقية (سرطان الغدة الدَّرقية الجريبي/ الحليمي المتقدم، سرطان الغدة الدَّرقية الكشمي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من سرطان المثانة (تنتشر على مرحلة موضعية أو متقدمة) لعلاج سرطان المثانة المبكر (السطحي)، يعطى الدَّواء كذلك في المثانة لمنع تكرار &quot;انتكاس&quot; سرطان المثانة بعد الجراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان المبيض المُعاود</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الكُلى الذي يحدث في سن معين في الأطفال (ورم ويلمز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الأنسجة العصبية الذي يحدث في الطفولة (الورم الأرومي العصبي المتقدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أيضًا استخدام دوكسوروبيسين بمصاحبة مضادات السرطان الأخرى.</p><p dir="RTL">بما أنَّ دوكسوروبيسين عقار مضاد للسرطان، فيجب أن يتلقى الشَّخص العلاج في قسم متخصص وتحت إشراف طبيب كفء في استخدام العقاقير المضادة للسرطان. وسوف يشرح لك فريق العمل في القسم الأشياء التي يجب إيلاء اهتمام خاص لها أثناء العلاج وبعده. وهذه التَّعليمات ستعمل على تذكيرك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دوكسوروبيسين إيبيفيه في الحالات الآتية</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه دوكسوروبيسين أو أي مكونات أخرى بهذا الدَّواء المدرجة في القسم 6 أو المُنتَجات الدَّوائية الأخرى التي تنتمي إلى نفس مجموعة الأدوية (ما يُسمى بالأنثراسيكلينات أو الأنثراسينديونات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء الحمل أو فترة الرضاعة</p><p dir="RTL">&nbsp;</p><p dir="RTL">بحسب طريقة الإعطاء، فإنه &quot;يجب عدم&quot; إعطاء عقار دوكسوروبيسين إيبيفيه لك</p><p dir="RTL">في الحالات الآتية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإعطاء في الوريد</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انخفض إنتاج خلايا الدَّم لديك، أو ضعفت وظيفة النخاع العظمي لديك (كبت النخاع العظمي) أو التهبت الأغشية المخاطية بالفم لديك (التهاب الفم) بسبب علاج سابق بإشعاع أو عقاقير مضادة للسرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا أو سابقًا من اضطرابات بالقلب (ذبحة صدرية [ضيق في الصدر]، قصور بعضلة القلب، اضطراب شديد بالنظم القلبي واضطراب التوصيل، اضطراب قلبي التهابي حاد، احتشاء عضلة القلب خلال آخر 6 أشهر، اضطرابات بعضلة القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور شديد في وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد سبق لك العلاج بالجرعة القصوى من عقاقير مماثلة مضادة للسرطان (أنْثراسيكلينات أخرى مثل إيبيروبيسين، إيداروبيسين أو داونوروبيسين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى حادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بشكل أكثر سهولة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب الأغشية المخاطية للفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإعطاء في المثانة</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان السرطان قد انتشر إلى جدار المثانة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى المسالك البولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى بالمثانة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعذر إخراج البول عبر قسطرة (أنبوب يتم إدخاله في المثانة لإخراج البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك دم يخرج في البول (بيلة دموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات خاصَّة بالاستخدام</strong></p><p dir="RTL">يرجى التحدث إلى الطبيب أو الصيدلي أو أحد أفراد الفريق الطبي المدربين قبل إعطائك عقار دوكسوروبيسين إيبيفيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيراقب الطبيب علاجك بعقار دوكسوروبيسين إيبيفيه عن كثب في الحالات الآتية</strong><strong>:</strong></p><ul><li dir="RTL">إذا كنت مريضًا من كبار السن.</li><li dir="RTL">إذا كان لديك تاريخ مرضي من الإصابة بمرض بالقلب.</li><li dir="RTL">إذا كان لديك تاريخ مرضي من الإصابة بكبت النخاع العظمي.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت من قبل علاجًا إشعاعيًّا على الصدر (المَنْصِف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد سبق لك العلاج بعقاقير مماثلة مضادة للسرطان (أنْثراسيكلينات أخرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات هامَّة حول عقار دوكسوروبيسين إيبيفيه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;من المحتمل أن يُسبب دوكسوروبيسين عقمًا دائمًا لدى كلٍّ من الرجال والسيدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وخز أو إحساس بالحُرقة في موضع حقن دوكسوروبيسين، فربما يكون ذلك ناجمًا عن تسرب العقار خارج الوريد. فيجب في هذه الحالات إبلاغ طبيبك فورًا. ستقوم/ سيقوم بإعطاء العقار في وريد آخر وسيراقب بعناية المنطقة المتأثرة بالتسرب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد سبق لك العلاج بدوكسوروبيسين (حتى 20 سنة مضت) وأصبحت حاملًا، فسيراقب الطبيب قلبك، حتى إذا لم تكوني مصابة بأي مشاكل بالقلب في الماضي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يصبح لون البول أحمر أثناء العلاج بدوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء العلاج بدوكسوروبيسين، قد تعاني من انزعاج شديد مثل: الغثيان، القيء والتهاب الأغشية المخاطية بالفم والأنف. يُرجى إبلاغ طبيبك فورًا إذا عانيت من أي مما سبق، وسيقوم بإعطائك العلاج اللازم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُوصى بعدم تلقي أي لقاحات أثناء العلاج بدوكسوروبيسين. ويجب أيضًا تجنب الاحتكاك &quot;التلامس&quot; مع الأشخاص الذين تم تطعيمهم مؤخرًا بلقاح ضد شلل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيقوم طبيبك بما يلي قبل وأثناء العلاج بعقار دوكسوروبيسين إيبيفيه</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّحقق من تعداد خلايا الدَّم لديك؛ لأنَّ العلاج بدوكسوروبيسين قد يؤدي إلى تلف بالنخاع العظمي، وهذا يقلل عدد خلايا الدَّم البيضاء ويجعلك أكثر عرضة للإصابة بالعدوى والنزيف. وقد يقلل طبيبك جرعة العلاج أو يوقفه أو يُؤجله إذا وجد أنك تعاني من كبت شديد بالنخاع العظمي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّحقق من الرئتين والصدر؛ للتأكد من أنَّ الرئتين تؤديان وظائفهما كما ينبغي أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إجراء مخطط كهربية القلب (رسم القلب) لتسجيل نشاط القلب؛ لأنَّ دوكسوروبيسين ربما يُسبب التهابًا (اعتلالًا) بعضلة القلب. وقد يحدث ذلك، على وجه الخصوص، إذا كان لديك تاريخ مرضي من الإصابة باضطراب قلبي، أو يزيد عمرك عن 70 سنة أو يقل عن 15 سنة، أو كنت قد خضعت من قبل للعلاج بدوكسوروبيسين (أو أنْثراسيكلينات أخرى مماثلة) أو تلقيت علاجًا إشعاعيًّا لتجويف الصدر. ويجب أَلَّا تتجاوز الجرعة الإجمالية (التراكمية) 450-550 مجم/ متر مربع لأنَّ الجرعات الأعلى تزيد بشدة من مخاطر حدوث فشل القلب، لا سيما لدى الأطفال والمرضى الذين لديهم تاريخ سابق من الإصابة بمرض بالقلب. وعادة ما تعتبر الجرعة القصوى للأطفال 300 مجم/ متر مربع (للأطفال أصغر من 12 سنة) وتصل إلى 450 مجم/ متر مربع (للأطفال بعمر 12 سنة فأكبر). قد تكون الجرعة القصوى الإجمالية أقل للرضع. وربما يُجري لك الطبيب أيضًا اختبارات أخرى لمراقبة وظائف القلب لديك (على سبيل المثال، تصوير الأوعية الدموية بالنكلويدات المشعة أو تخطيط صدى القلب [أشعة تصوير البطين بالنظائر المشعة]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مراقبة مستوى حمض اليوريك في دمك؛ للتَّأكد من أنك تحصل على السوائل الكافية؛ لأنَّ دوكسوروبيسين يزيد مستويات حمض اليوريك في الدَّم لديك (فرط حمض اليوريك بالدَّم). ويُرجى إبلاغ طبيبك إذا لاحظت أي ألم في المفاصل أو أعراض للنقرس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص الفم والحلق بشكل منتظم؛ لأنَّ دوكسوروبيسين قد يسبب تغييرات في الأغشية المخاطية بالفم والحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مراقبة وظائف الكُلى لديك. فقد يكون من الضَّروري خفض الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مراقبة وظائف الكبد لديك (من خلال إجراء اختبارات دم). فقد يكون من الضَّروري خفض الجرعة إذا كان هناك قصور في وظائف الكبد. وإذا كنت قد عانيت من التهاب الكبد من النوع &quot;بي&quot; أو &quot;سي&quot; في الماضي، فقد ينشط هذا المرض ثانية نتيجة العلاج بدوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّحقق من الحالة الصحية العامة؛ لأنَّه لا يجب إعطاء دوكسوروبيسين إذا كان الشخص يعاني من أي التهابات أو قرح أو إسهال. سيعالجك الطبيب من أي عدوى لديك قبل إعطائك دوكسوروبيسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار دوكسوروبيسين إيبيفيه بمصاحبة عقاقير أخرى</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيادلة إذا كنت تتناول/ تستخدم أو قد تناولت/ استخدمت مؤخرًا أو كنت تنوي تناوُل/ استخدام عقاقير أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إبلاغ طبيبك على الفور في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول في الوقت نفسه عقاقير أخرى لعلاج السرطان مثل: الأنْثراسيكلينات (داونوروبيسين، إيبيروبيسين، إيداروبيسين)، سِيسْبلاتين، سيكلوفوسفاميد، سيكلوسبورين، سيتارابين، داكاربازين، داكتينومايسين، 5-فلورويوراسيل، ميتوميسن سي وتاكسينات؛ لأنها قد تلحق تلفًا بالقلب. كذلك، قد يلحق إعطاء دوكسوروبيسين بمصاحبة سيتارابين تلفًا بالقولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول في الوقت نفسه عقاقير تُؤثر على وظائف القلب لديك (مثل مناهضات الكالسيوم، فيراباميل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت من قبل، أو ستخضع قريبًا، للعلاج بعقار تراستوزوماب (عقار مضاد للسرطان)؛ إذ ربما يتوجب على الطبيب مراقبة وظائف القلب لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع حاليًا، أو خضعت من قبل للعلاج بعقار باكليتاكسيل (عقار مضاد للسرطان)؛ لأنه ربما يزيد من التأثيرات والآثار الجانبية لدوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول باربيتورات (أقراص منومة معينة) أو رِيفامبيسِين (مضاد حيوي)؛ لأنَّ كمية دوكسوروبيسين في الدَّم قد تنخفض في هذه الحالة، وبالتَّالي ربما تقل فعالية دوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت من قبل للعلاج بعقار 6-ميركابتوبيورين، ميثوتريكسات أو ستربتوزوسين (عقار لعلاج السرطان)؛ لأنَّ هذا قد يزيد من مخاطر الآثار الجانبية في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بعقاقير تؤثر على النخاع العظمي، مثل السالفوناميدات (لعلاج العدوى)، كلورامفينيكول (لعلاج العدوى)، فينيتوين (لعلاج الصرع)، مشتقات أميدوبيرين (لعلاج الألم والالتهابات) والعقاقير المضادة للفيروسات القهقرية (الرجعية) (لعلاج الإيدز، مثل ريتونافير). فقد يُؤدي ذلك إلى كبت النخاع العظمي ونقص عدد خلايا الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول سيكلوسبورين (لكبت المناعة الطبيعية) أو سيميتيدين (لعلاج قرح المعدة)؛ لأنَّ ذلك قد يزيد من مستوى دوكسوروبيسين في الدَّم. وقد يضع الطبيب في الاعتبار خفض الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى حاليًا أو تلقيت سابقًا أو سوف تتلقى علاجًا إشعاعيًّا؛ لأنَّ ذلك قد يزيد من معدل حدوث الآثار الجانبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تناولت من قبل سيكلوفوسفاميد (عقارًا مضادًّا للسرطان)؛ لأنَّ هذا قد يزيد مخاطر الآثار الجانبية على المثانة (التهاب المثانة النزفي، عدوى في المثانة تتسبب في بعض الأحيان في خروج دم في البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقير لخفض مستوى حمض اليوريك. إذ ربما يكون من الضَّروري ضبط جرعات هذه العقاقير؛ لأنَّ دوكسوروبيسين قد يزيد من مستوى حمض اليوريك في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ديجوكسِين (لعلاج أمراض القلب)؛ لأنَّ فعالية ديجوكسِين قد تقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقير تستخدم في علاج الصرع مثل: فينيتوين، كَرْبامازِيبين وفالبروات؛ لأنَّ تأثير هذه العقاقير قد يقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج في الوقت نفسه بالبروجيستيرون (هرمون الجسم الأصفر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يتم إعطاؤك كلوزابين (عقارًا يُستخدم في علاج الذهان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج كذلك بعقار هيبارين (لمنع حدوث تجلط دموي) أو 5-فلورويوراسيل (عقار مضاد للسرطان). إذ إنَّ دوكسوروبيسين قد يرتبط بتلك العقاقير، إذا تم إعطاؤه معها في نفس التَّسريب، ويجعلها غير فعالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج بأمفوتريسين بي، وهو عقار يُستخدم لعلاج العدوى الفطرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقير مدرة للبول أو مضادة لمرض السكري (مثل سالفوناميد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد تلقي أحد اللقاحات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحَمْل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يُرجى طلب المشورة من طبيبكِ أو الصيدلي الخاص بكِ قبل تلقي هذا العقار إذا كنتِ تتوقعين أنكِ قد تكونين حاملًا، أو تخططين أن تصبحي حاملًا أو إذا كنتِ مرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطاء عقار دوكسوروبيسين إيبيفيه أثناء فترة الحمل والرضاعة الطبيعية. ويجب على السيدات تجنُّب الحَمْل أثناء فترة العلاج بدوكسوروبيسين وحتى 6 أشهر بعد الانتهاء من العلاج؛</p><p dir="RTL">حيث لا يمكن استبعاد احتمالية تعرض الطفل لضرر. يجب عليكِ استخدام أحد موانع الحمل الفعَّالة أثناء العلاج وحتى 6 أشهر من انتهاء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويجب على الرجال استخدام وسيلة منع حمل مناسبة أثناء فترة العلاج بدوكسوروبيسين وحتى 6 أشهر بعد الانتهاء من العلاج؛ لأنَّ التركيب الوراثي قد يلحقه ضرر ولضمان عدم حمل زوجاتهم أثناء تلك الفترة.</p><p dir="RTL">يُرجى استشارة طبيبك إذا كنت تفكر في الإنجاب بعد العلاج. لأنَّ دوكسوروبيسين ربما يُسبب عقمًا غير قابل للارتداد، فإنه يُوصى بمناقشة الطبيب بشأن خيار حفظ الحيوانات المنوية بالتجميد قبل العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات وتشغيل الآلات</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_17" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:490.5pt;
 margin-top:.35pt;width:33pt;height:23.25pt;z-index:-251656704;visibility:visible;
 mso-position-horizontal-relative:page'>
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="44" height="31" src="file:///C:/Users/abulase1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" />تحذير: قد يُؤثر هذا العقار على ردود أفعالك وقدرتك على قيادة المركبات.نظرًا لتكرار حدوث الغثيان والقيء، فإنه يوصى بعدم قيادة المركبات أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار دوكسوروبيسين إيبيفيه على الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الدَّوائي على ما يقرب من 133.8 مجم صوديوم لكل متر مربع من مساحة سطح الجسم. ويجب أخذ ذلك في الاعتبار إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم علاجك بعقار دوكسوروبيسين إيبيفيه من قبل طبيب. وقد يطلب منك الطبيب إجراء بعض الاختبارات، مثل: اختبارات الدَّم ورسم القلب الكهربائي، قبل أو أثناء العلاج بعقار دوكسوروبيسين إيبيفيه؛ لتحديد الجرعة المناسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء عقار دوكسوروبيسين إيبيفيه في الوريد عن طريق التسريب الوريد أو في المثانة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتم عمليات التحضير والإعطاء من قبل فريق طبي مدرب في مستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستعتمد الجرعة على سنك (ربما تكون الجرعات الأقل مطلوبة للمرضى من الأطفال وكبار السن)، والوزن والحالة الصحية العامة. وستعتمد كذلك على كل علاجات السرطان الأخرى التي ربما تكون قد خضعت لها من قبل. سيقوم طبيبك بحساب سطح جسمك بالمتر المربع. وستتلقى العقار كل 3 أسابيع لمدة تتراوح بين 6 و12 شهرًا. ومن الممكن تكرار الإعطاء في المثانة على فترات فاصلة تبلغ أسبوعًا إلى شهر. ويعتمد طول فترة العلاج المحددة على حالتك الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من أمراض بالكبد أو الكُلى</strong></p><p dir="RTL">قد يكون من الضَّروري خفض الجرعة إذا كان هناك قصور بوظائف الكبد أو قصور شديد بوظائف الكُلى.</p><p dir="RTL">يجب أَلَّا يتم إعطاؤك عقار دوكسوروبيسين إيبيفيه إذا كان هناك قصور شديد في وظائف الكبد لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تجاوز الجرعة المقررة من عقار دوكسوروبيسين إيبيفيه </strong></p><p dir="RTL">من غير المرجح أن تتلقى جرعة زائدة؛ إذ إنَّ العقار سيتم إعطاؤه من قبل الطبيب. ومع ذلك، إذا كان الشك يساورك، فيُرجى إخبار الطبيب أو أحد أفراد الطاقم الطبي المدربين <strong><u>فورًا</u></strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تعاني من آثار جانبية على الجهاز الهضمي (خاصَّة التهاب الأغشية المخاطية) والقلب خلال 24 ساعة بعد تلقي جرعة عالية مفردة من دوكسوروبيسين. كما قد يحدث كبت شديد في النخاع العظمي بعد مرور 10 إلى 14 يومًا. وقد يكون ذلك مصحوبًا بمخاطر متزايدة لحدوث نزيف ومعدل حدوث الكدمات (نقص الصَّفائح الدَّموية) بالإضافة إلى مخاطر متزايدة لحدوث عدوى (من نقص كرَيَّاتِ الدَّم البيْضاء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاء العلاج في مستشفى ويتضمن إعطاء مضادات حيوية (عقاقير لعلاج العدوى)، نقل دم (خاصَّة خلايا الدَّم البيضاء وصفائح الدَّم) وعلاج الآثار الجانبية على الجهاز الهضمي</p><p dir="RTL">والقلب. وربما يتم نقلك إلى غرفة معقمة. وإذا عانيت من آثار جانبية على القلب، سيفحصك طبيب أمراض القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب الإعطاء غير المقصود خارج الوريد آثارًا جانبية موضعية شديدة، بما في ذلك موت الأنسجة (نخر) والتهاب الوريد مع تكون تجلط دموي (التهاب الوريد الخثاري). وربما يكون الإحساس بحرقة في منطقة موضع التَّسريب علامة على ذلك ويجب حينئذ إخبار طبيبك<u> </u><strong><u>على الفور</u></strong> إذا اشتبهت في حدوث ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ملحوظة للطبيب: للاطلاع على معلومات حول الجرعات الزَّائدة، يُرجى الرجوع إلى نهاية النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى الاتصال بطبيبك أو الصيدلي الخاص بك، إذا كان لديك أي أسئلة إضافية فيما يتعلق باستخدام هذا العقار.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع العقاقير، قد يكون لهذا العقار آثار جانبية ومع ذلك قد لا تظهر لدى جميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إبلاغ طبيبك فورًا إذا لاحظت أيًّا مما يلي:</p><ul><li dir="RTL">تفاعل حساسية يُسبب تورم الشفتين، الوجه أو الرقبة، ويُؤدي بدوره إلى ضيق شديد في التَّنفس، طفح جلدي أو شرى (وذْمة عصبِية وِعائِيّة) أو صدمة تأقية (انخفاض شديد في ضغط الدَّم، شحوب اللون، هِياج، ضعف النبض، ضعف الوعي).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاجًا شديدًا مثل الغثيان، القيء والتهاب الأغشية المخاطية للفم والأنف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحتاج إلى رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون بعض الآثار الجانبية شديدة جدًّا وتستلزم وضع المريض تحت المراقبة بعناية. وبعض الآثار الجانبية تتوقف على سرعة الإعطاء بالإضافة إلى نوع الجرعة. ويعد كبت النخاع العظمي أحد تلك الأمثلة وقد يكون شديدًا جدًّا بالرَّغم من أنه يكون مؤقتًا عادة. والأعراض الشَّائعة لتضرر النخاع العظمي هي: الحمى، العدوى، تسمم الدَّم (تعفن الدَّم، مما يعني وجود بكتيريا في الدَّم بسبب كبت الجهاز المناعي)، صدمة نتيجة تسمم الدَّم (صدمة إنتانية مصحوبة بانخفاض شديد في ضغط الدَّم، شحوب اللون، هياج، ضعف وسرعة النبض، تعرق الجلد، فقدان الوعي)، نزيف، نقص الأوكسجين بالأنسجة ونخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُسبب الإعطاء غير المقصود خارج الوريد التهابًا شديدًا بالجلد (التهاب الخلايا)، بثورًا بالجلد، التهاب الوريد مع تكون تجلط دموي (التهاب الوريد الخثاري)، التهاب الأوعية الليمفاوية، والتي تتسم بوجود علامات مخططة حمراء مؤلمة تحت الجلد، ونخر موضعي بالخلايا ربما يستلزم التدخل الجراحي (بما في ذلك ترقيع &quot;نقل&quot; الجلد).</p><p dir="RTL"><!--[if gte vml 1]><v:group
 id="Group_x0020_8" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:78.4pt;margin-top:37.9pt;width:445.75pt;height:94.4pt;
 z-index:-251660800;mso-position-horizontal-relative:page' coordorigin="1568,758"
 coordsize="8915,1888" o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:group id="Group_x0020_15" o:spid="_x0000_s1027" style='position:absolute;
  left:1578;top:768;width:2;height:1868' coordorigin="1578,768" coordsize="2,1868"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_16" o:spid="_x0000_s1028" style='position:absolute;
   left:1578;top:768;width:2;height:1868;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l,1868e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,768;0,2636"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_13" o:spid="_x0000_s1029"
  style='position:absolute;left:10473;top:768;width:2;height:1868'
  coordorigin="10473,768" coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_14" o:spid="_x0000_s1030" style='position:absolute;
   left:10473;top:768;width:2;height:1868;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="2,1868" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l,1868e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,768;0,2636"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_11" o:spid="_x0000_s1031"
  style='position:absolute;left:1573;top:763;width:8905;height:2'
  coordorigin="1573,763" coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_12" o:spid="_x0000_s1032" style='position:absolute;
   left:1573;top:763;width:8905;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l8905,e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;8905,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_9" o:spid="_x0000_s1033"
  style='position:absolute;left:1573;top:2641;width:8905;height:2'
  coordorigin="1573,2641" coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="Freeform_x0020_10" o:spid="_x0000_s1034" style='position:absolute;
   left:1573;top:2641;width:8905;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="8905,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQARu3b7wQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE89a8Mw
EN0D/Q/iCt1iORlMcS2HEGjJFuo2Q7ardbXdSCfHUmzn31eFQrZ7vM8rNrM1YqTBd44VrJIUBHHt
dMeNgs+P1+UzCB+QNRrHpOBGHjblw6LAXLuJ32msQiNiCPscFbQh9LmUvm7Jok9cTxy5bzdYDBEO
jdQDTjHcGrlO00xa7Dg2tNjTrqX6XF2tgrcKv9YmO64uxv2Y0/aKh1t2Uerpcd6+gAg0h7v4373X
cX4Gf7/EA2T5CwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABG7dvvBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" path="m,l8905,e" filled="f" strokeweight=".5pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;8905,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]-->تم الإبلاغ عن حدوث الآثار الجانبية التَّالية بمعدّلات التكرار التقريبية الآتية:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; شائعة جدًّا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُؤثر في أكثر من مريض واحد من بين كل 10 مرضى</p><p dir="RTL">شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُؤثر في ما يصل إلى مريض واحد من بين كل 10 مرضى</p><p dir="RTL">غير شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُؤثر في ما يصل إلى مريض واحد من بين كل 100&nbsp;مريض</p><p dir="RTL">نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُؤثر في ما يصل إلى مريض واحد من بين كل 1000 مريض</p><p dir="RTL">نادرة جدًّا:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُؤثر في ما يصل إلى مريض واحد من بين كل 10000 مريض</p><p dir="RTL">غير معروفة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة جدًّا</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، قيء، إسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (ثعلبة، اعتمادًا على الجرعة، وينمو الشعر ثانية في معظم الحالات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول إلى اللون الأحمر (بعد العلاج بدوكسوروبيسين بيوم أو يومين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كبت النخاع العظمي، بما في ذلك انخفاض عدد خلايا الدَّم البيضاء وصفائح الدَّم، وانخفاض عدد خلايا العدلات، أحد خلايا الدَّم البيضاء، والذي قد يكون مصحوبًا أيضًا بحمى (قلة خلايا العَدِلات الحموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات عامة شديدة بتعداد خلايا الدَّم (قلة الكريات الشاملة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الأوكسجين بالأنسجة أو نخر الأنسجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنيميا &quot;فقر الدَّم&quot; (انخفاض عدد خلايا الدَّم الحمراء، مما قد يُؤدي إلى شحوب لون البشرة وضعف أو عُسْر التَّنَفُّس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف عضلة القلب (السمية القلبية). وتزيد هذه المخاطرة لدى المرضى الذين يخضعون للعلاج الإشعاعي أو يعالجون بعقاقير أخرى سامة للقلب، ولدى المرضى الأكبر من 70 عامًا أو الأصغر من 15 عامًا ولدى المرضى الذين يعانون من حالات مرضية إضافية مثل: الأنيميا، التهاب التأمور والتهاب عضلة القلب. وهذه الآثار قد تحدث بعد بدء العلاج بوقت قصير أو بعد عدة سنوات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المخاطية للأنف، الفم أو المهبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو تقرح الأغشية المخاطية في الفم (الْتِهاب الفَم) أو المريء (التهاب المريء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فرط حساسية الجلد تجاه الضوء الطبيعي والصناعي (حساسية تجاه الضوء)، احمرار الجلد، الطفح الجلدي (الطفح الظَّاهر) والأعراض الموضعية للتسمم (التسمم الموضعي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال الأظافر (انحلال الأظافر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، قشعريرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف/ فقدان الطاقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة مع تجلط الدَّم (التهاب الوريد الخثاري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحصول على نتائج غير طبيعية لفحوصات قلب معينة (انخفاض عديم الأعراض للكسر القذفي للبطين الأيسر)، الحصول على نتيجة غير طبيعية لمخطط كهربية القلب (رسم القلب)، قيم غير طبيعية لإنزيمات الكبد (ناقِلَة الأمين)، زيادة الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تسمم الدَّم (تعفن الدَّم)، تسمم الدَّم مع التهاب معدي (الإنتان الدموي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المُلْتَحِمَة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطرابات النَّظم القلبي (عدم انتظام ضربات القلب أو تسارعها أو تباطؤها)، انخفاض مقدار الدَّم الذي يتم ضخه عبر غرفة القلب اليسرى في الجسم، قصور يحتمل أن يكون مميتًا في عضلة القلب (اعْتِلال عَضَلَةِ القَلْب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن أو إحساس بالحُرقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات التهابية في مناطق تعرضت من قبل للعلاج الإشعاعي (ما يُسمى تفاعل المعاودة الإشعاعية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط تصبغ الجلد والأظافر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شَرَى (أرتكاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحَقن، بما في ذلك احمرار الجلد بطول الوريد، التهاب بالأوردة، زيادة سمك أو صلابة جدران الأوعية الدموية (التصلب الوريدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث الآثار الجانبية الشَّائعة التَّالية بعد الإعطاء في المثانة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المثانة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضيق عند التبول أو صعوبة التبول أو ألم عند التبول (عُسْر التَّبَوُّل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تهيُّج المثانة أو المسالك البولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إلحاح التبول ليلًا (التبول الليلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كثرة التبول (التبول المتكرر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إلحاح التبول المصحوب بألم (تقطير البول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التقطير المتكرر لكميات صغيرة من البول (تَبْوال &quot;زيادة تكرار التبول&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;وجود دم بالبول (بيلة دموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تقلصات المثانة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نخر الأنسجة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب المثانة مما يتسبب في وجود دم بالبول (التهاب المثانة النزفي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير شائعة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تسمم الدَّم مع حالات شبيهة بالصدمة (صدمة إنتانية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قد يُسبب دوكسوروبيسين أنواعًا معينة من سرطان الدَّم، وكذلك بمصاحبة عقاقير أخرى لعلاج السرطان. وهذه الأشكال من السرطان تظهر أعراضها خلال سنة إلى 7 سنوات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انسداد وعاء دموي من خلال تجلط دموي (الانصمام الخثاري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نزيف في المعدة أو الأمعاء، التهاب في الأمعاء والأغشية المخاطية للمعدة، نخر في أنسجة القولون مع نزيف مفرط وعدوى شديدة في حالة إعطاء دوكسوروبيسين بمصاحبة سيتارابين (عقار لعلاج السرطان).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نادرة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تورم (وذمة وعائية) بالجفون واللسان مع ضعف التَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صدمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضعف التَّنفس، تورم الأغشية المخاطية للأنف، تسارع التنفس وصعوبته، التهاب رئوي ناجم عن العلاج الإشعاعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الإعطاء غير المقصود خارج الوريد، الذي قد يُسبب التهابًا شديدًا بالنسيج تحت الجلد والدَّم والأوعية الليمفاوية وبثورًا بالجلد ونخرًا موضعيًّا بالأنسجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نادرة جدًّا</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية يسبب ضيقًا في التنفس أو دَوْخَة (فرط حساسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النظم القلبي (تغييرات غير محددة في رسم القلب الكهربائي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات فردية من اضطرابات النظم القلبي التي يحتمل أن تكون مميتة، فشل البطين الأيسر بالقلب، التهاب كيس التأمور المحيط بالقلب مما يسبب ألمًا في الصدر واحتباس السوائل حول القلب (التهاب التأمور)، التهاب عضلة القلب وكيس التأمور (متلازمة التهاب عضلة القلب-التهاب التأمور)، فقدان النبض العصبي في القلب (إحصارًا أذينيًّا بطينيًّا، إحصار الحزيمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح بالأغشية المخاطية للفم، الحلق، المريء، المعدة أو الأمعاء، تغير لون الأغشية المخاطية بالفم (فرط تصبغها).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وتنميل في اليدين والقدمين (احمرار طرفي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأنسجة، خاصة في اليدين والقدمين، مما يؤدي إلى احمرار، تورم، بثور بالجلد، وخز أو إحساس بالحُرقة ناجم عن تسرب العقار في الأنسجة (ضعف الحس الاحمراري، متلازمة باليد والقدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضعف عام في العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الفشل الكلوي الحاد (حالات فردية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة مستويات حمض اليوريك في الدَّم (فرط حمض اليوريك بالدَّم) النَّاجم عن التحلل السريع للورم مما قد يُسبب الإصابة بالنَّقرس، تكون حصوات بالكُلى أو تلف الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;توعُّك عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير معروفة</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام الاستقلاب الناجم عن التحلل السريع لخلايا الورم (متلازمة انحلال الورم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات ساخنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس بسبب التقلصات بعضلات الجهاز التَّنفسي (التشنجات القصبية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مؤقتة بمستوى إنزيمات الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تلف شديد بالكبد، والذي قد يتدهور إلى تلف دائم في أنسجة الكبد (تليُّف الكبد) في بعض الحالات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب القرنية، زيادة إفراز الدموع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم شديد بالمفاصل وتورمها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الضرر النَّاجم عن الإشعاع (بالجلد، الرئتين، المريء، الأغشية المخاطية بالجهاز الهضمي، القلب) الذي بصدد الشفاء، قد يعود بعد العلاج بدوكسوروبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ظهور بقع سميكة أو حرشفية أو متقشرة على الجلد (تقران سفعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انقطاع الحيض (الطمث).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضعف الخصوبة لدى الرجال (نقص الحيوانات المنوية النشطة أو انعدامها).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا لاحظت حدوث أيَّة آثار جانبية، فيجب أن تتصل بطبيبك أو الصيدلي الخاص بك أو الفريق الطبي المُدرَّب. يشمل هذا الآثار الجانبية غير المدرجة بهذه النَّشرة.</p><p dir="RTL">من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في زيادة المعلومات حول أمان استخدام هذا العقار.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في الثلاجة (عند 2&mdash;8 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ المنتج الدَّوائي في العبوة الأصلية، لحماية المحتويات من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن يُؤدي تخزين المحلول المعد للحقن في الثلاجة إلى تكون منتجًا هلاميًّا. يعود هذا المنتج الهلامي إلى محلول لزج إلى حد ما، ثم إلى محلول متحرك بعد 2 إلى 4 ساعات في درجة حرارة الغرفة المضبطة (15 درجة إلى 25 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">للاستخدام مرة واحدة فقط. تخلَّص مما تبقى من العقار. قم بحفظ هذا العقار بعيدًا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد &quot;تاريخ انتهاء الصلاحية&quot; الموضح على العبوة الكرتونية الخارجية</p><p dir="RTL">والملصق. يشير تاريخ الصلاحية إلى آخر يوم من الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التَّخلص من أيَّة أدوية متبقية وأيَّة عبوات رئيسية باعتبارها نفايات خطرة وفقًا للوائح المعمول بها.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دوكسوروبيسين هو المادة الفعالة.</p><p dir="RTL">1 مللي لتر محلول مُركَّز؛ لإعداد محلول التَّسريب يحتوي على 2 مجم دوكسوروبيسين في هيئة هيدروكلوريد الدوكسوروبيسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كلوريد الصوديوم، محلول حمض الهيدروكلوريك لضبط قيمة درجة الحموضة، ماء لأغراض الحَقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول أحمر، صافٍ.</p><p dir="RTL">زجاجات مصنوعة من الزجاج من النوع الأول، وفقًا لهيئة دستور الأدوية الأوروبي، مُزودة بسدادة مطاطية رمادية من الكلوروبوتيل مطلية بالتيفلون وغطاء من الألومينْيوم، ومعبأة في عبوة كرتونية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">زجاجة واحدة &times; 5 مللي لتر</p><p dir="RTL">5 زجاجات &times; 5 مللي لتر</p><p dir="RTL">10 زجاجات &times; 5 مللي لتر</p><p dir="RTL">زجاجة واحدة &times; 25 مللي لتر</p><p dir="RTL">زجاجة واحدة &times; 50 مللي لتر</p><p dir="RTL">زجاجة واحدة &times; 100 مللي لتر</p><p>عبوات زجاجية ذات/ بدون حاوية بلاستيكية صافية (ONKO-Safe). قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة إيبيفيه فارما المحدودة Nfg. شراكة محدودة، 4866 أونتراخ، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Doxorubicin "Ebewe" 2 mg/ml – Concentrate for solution for infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 2 mg doxorubicin hydrochloride.
Each 5 ml vial contains 10 mg of doxorubicin hydrochloride. Each 25 ml vial contains 50 mg of doxorubicin hydrochloride Each 50 ml vial contains 100 mg of doxorubicin hydrochloride Each 100 ml vial contains 200 mg of doxorubicin hydrochloride


For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
 Clear, red coloured solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin is used in the following indications: soft tissue and osteogenic sarcomas, Hodgkin`s disease and non-Hodgkin`s lymphoma, acute lymphoblastic leukaemia, acute myeloblastic leukaemia, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.</p><p>Doxorubicin is used intravesically for the treatment of transitional cell carcinoma, papillary bladder tumours and carcinoma in situ. It should not be used for invasive tumours of the bladder which have penetrated the bladder wall, patients with urinary tract infections or inflammatory conditions of the bladder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doxorubicin may be given by</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous (bolus) injection over 2-5 minutes or as continuous infusion into a running infusion of sodium chloride 0.9% w/v intravenous injection, dextrose intravenous injection 5% w/v or sodium chloride and dextrose intravenous injection.</p><p>&nbsp;</p><p>Bolus injection causes higher peak plasma-concentrations and therefore is probably more cardiotoxic. <u>Adult dosage</u></p><p><u>Monotherapy</u></p><p>Dosage&nbsp; depends&nbsp; on&nbsp; tumor&nbsp; type,&nbsp; cardiac&nbsp; or&nbsp; hepatic&nbsp; function,&nbsp; and&nbsp; concurrent&nbsp; chemotherapy.&nbsp;&nbsp; <u>The recommended dose as single agent: </u>The commonly recommended dosage schedule as single agent is 60-75 mg/m&sup2; by intravenous injection, once every three weeks. An alternative dose schedule is</p><p>20 mg/m&sup2; intravenously, for three consecutive days, once every three weeks. <u>The maximum cumulative dose: </u>550 mg/m&sup2; should not be exceeded.</p><p>&nbsp;</p><p>Administration of doxorubicin in a weekly regimen has been shown to be as effective as the 3-weekly regimen whilst reducing cardiac toxicity. The recommended dosage is 20 mg/m&sup2; weekly, although objective responses have been seen with doses between 6 and 12 mg/m&sup2;.</p><p>&nbsp;</p><p><u>Combination therapy</u></p><p>&nbsp;</p><p>Dosage should be decreased when combination with other cytostatic drugs with any similar toxicity is used.</p><p>The maximum cumulative dose should be reduced from 450 mg/m2 to 400 mg/m2 if a patient received mediastinal irradiation, has concomitant heart disease, or is also treated with other cardiotoxic, non- anthracycline oncolytics.</p><p>&nbsp;</p><p><u>Dosage adjustments in specific patient groups:</u></p><p><u>Hepatic dysfunction: </u>Dosage should be reduced in patients with impaired hepatic function. Doxorubicin dosage should be reduced if the bilirubin is elevated as follows: serum bilirubin 12 to&nbsp;&nbsp;&nbsp; 30 mg &ndash; give &frac12; of the normal dose, bilirubin &gt; 30 mg &ndash; give &frac14; of the normal dose.</p><p><u>Renal dysfunction:</u></p><p>In general, impaired renal function does not require dose reduction.</p><p>&nbsp;</p><p><u>Patients with cardiac risk:</u></p><p>Patients at increased risk for cardiotoxicity should be considered for treatment with a 24 hours continuous infusion, rather than bolus injection. In this way, cardiotoxicity may be less frequent, without a reduction in therapeutic efficacy. In these patients, the ejection fraction should be measured before each course.</p><p>&nbsp;</p><p>The risk of development of cardiomyopathy gradually increases with the dosage. A cumulative lifetime dose of 450-550 mg/m&sup2; should not be exceeded.</p><p>&nbsp;</p><p>In case of preexisting heart disease or prior radiotherapy to the heart or the mediastinum, cumulative doses of more than 400 mg should be avoided (Monitoring of the cardiac function &ndash; see section 4.4. Special Warnings).</p><p>In combination with other oncolytics doses of 50-75 mg/m&sup2; are administered. Myelosuppression may be more pronounced because of the additive effects of the drugs.</p><p>&nbsp;</p><p>Dosage in children</p><p>Dosage for children should be lowered since they have an increased risk of cardiotoxicity especially delayed cardiotoxicity and therefore follow-up cardiac evaluation is recommended.</p><p>Myelotoxicity should be anticipated, with nadirs at 10 to 14 days after start of treatment, but is usually followed by a rapid recovery due to the large bone marrow reserve of children as compared to adults.</p><p>&nbsp;</p><p>Superficial bladder carcinoma and bladder carcinoma in situ</p><p>The recommended dosage is 50 mg in 50 ml normal saline, administered via a sterile&nbsp; catheter. Initially, this dose is given weekly, later on monthly. The optimal duration of treatment has not yet been determined; it ranges from 6 to 12 months.</p><p>Restrictions regarding the maximal cumulative dose, as with intravenous administration, do not apply to intravesical administration, because systemic absorption of doxorubicin is negligible.</p><p>&nbsp;</p><p>Take care in the administration to avoid the possiblity of perivenous infiltration resulting in local necrosis and thrombophlebitis.</p><p>&nbsp;</p><p>Doxorubicin must not be given intrathecally or intramuscularly, subcutan or by long term infusion. (Since doxorubicin is reported to form precipitates in combination with heparin and 5 -fluorouracil, it should not be mixed with any other drug.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Doxorubicin is contra-indicated in patients who have a marked myelosuppression (e.g. induced by  previous anti-tumour treatment), in pre-existing or acute cardiac insufficiency or in patients who have previously received the maximum cumulative dose of doxorubicin or daunorubicin.

The presence of bucccal ulceration; this may be preceded by premonitory buccal burning sensations and repetition of treatment in the presence of this symptom is not advised.
 

During pregnancy and breast feeding.

Hypersensitivity to doxorubicin, chemically related products or any other excipient.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General precautions:</p><p>Doxorubicin should only be administered under the supervision of a physician experienced in the use of chemotherapy. It is recommended that the patient be hospitalised during at least the first phase of treatment since close observation and laboratory monitoring is necessary. Prior to treatment with doxorubicin, cardiac and hepatic function and haematology baseline tests should be carried out.</p><p>&nbsp;</p><p>Nausea, vomiting and mucositis are often extremely severe and should be treated appropriately. Doxorubicin should not be administered intramuscularly or subcutaneously.</p><p>&nbsp;</p><p>Extravasation:</p><p>Extravasation results in a severe and progressive tissue necrosis. Extravasation is signified by pain and/or a burning sensation at the site of intravenous administration of doxorubicin. If extravasation occurs, the injection should be terminated immediately and restarted in another vein. Ice packs should be applied to the site of extravasation. Flooding with normal saline, local infiltration with corticosteroids, or sodium hydrogencarbonate solution (8.4%), and application of dimethylsulfoxide have been reported with varying success. Local application of hydrocortisone cream 1% may be beneficial. The advice of the plastic surgery consultant should be asked for, and wide excision of the involved area should be considered.</p><p>&nbsp;</p><p>Cardiotoxicity:</p><p>There is an established risk of development of anthracycline induced cumulative dose dependent cardiomyopathy, therefore cumulative dose of 450-550 mg/m&sup2; should not be exceeded. At doses above&nbsp; this the risk of development of cardiac failure increases considerably. Reduction of the cumulative dose is the most important means of avoiding doxorubicin cardiotoxicity. The cardiotoxicity of doxorubicin may manifest as tachycardia, ECG changes or cardiac failure which may occur suddenly up to several months/years after discontinuation of treatment without preceding ECG changes. The risk of developing heart failure in cancer patients treated with doxorubicin persists throughout life. Cardiac failure due to doxorubicin may be unresponsive to conventional treatment.</p><p>&nbsp;</p><p>The risk of cardiotoxicity increases in patients previously treated with mediastinal or pericardial&nbsp; irradiation, in patients treated with other or previous anthracyclines and/or anthracenediones, in patients with a history of cardiac disease, in elderly patients (age <u>&gt; </u>70 years) as well as in children below 15 years. Cardiotoxicity may occur at doses lower than the recommended cumulative limit. The total cumulative dose of doxorubicin to an individual patient should therefore take into account any previous or concomitant treatment with other potentially cardiotoxic drugs or therapy such as high dose IV cyclophosphamide, mitomycin C or dacarbazine, other anthracyclines such&nbsp; as&nbsp; daunorubicin,&nbsp; or mediastinal or pericardial irradiation.</p><p>&nbsp;</p><p>Acute severe arrhythmias have been reported to occur during or within a few hours after doxorubicin administration.</p><p>&nbsp;</p><p>ECG changes may occur including a reduction in the voltage of the QRS wave, and a prolongation of the systolic time interval, and the ejection fraction may be reduced.</p><p>&nbsp;</p><p>Extreme care should be taken in patients with existing heart disease, such as a recent myocardial&nbsp; infarction, heart failure, cardiomyopathy, pericarditis or dysrhythmias, or in patients who have received other cardiotoxic agents such as cyclophosphamide (see section 4.5).</p><p>&nbsp;</p><p>&nbsp;</p><p>Monitoring of the cardiac function:</p><p>Cardiac function should be assessed prior to the start of treatment and should be carefully monitored throughout treatment and assessed after the doxorubicin therapy. An ECG before and after each treatment is recommended. Changes in ECG such as depression or negative T-wave, decrease in the ST-segment or arrhythmias are usually signs of an acute but transient (reversible) toxic effect and are not considered indications for suspension of doxorubicin therapy. However a persistent reduction in&nbsp; the amplitude of QRS-wave and a prolongation of the systolic interval are considered more indicative of anthracycline induced cardiotoxicity.</p><p>When the voltage of the QRS wave decreases by 30 % or at a fractional shortening of 5 % it is recommended that treatment be stopped.</p><p>&nbsp;</p><p>The optimum method of prediction of cardiomyopathy is detection of a reduction of the left&nbsp; ventricular ejection fraction (LVEF), determined by ultrasound or a heart scintigraphy. LVEF investigation should be performed prior to treatment and repeated after each cumulative dose of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;100 mg/m&sup2; and at any clinical signs of cardiac failure. As a rule an absolute decrease of &gt; 10% or a decrease below 50% in patients with normal initial LVEF-values is a sign of impairment of cardiac function. Continued treatment with doxorubicin in such patients must be carefully evaluated.</p><p>&nbsp;</p><p>Myelosuppression:</p><p>The high incidence of bone marrow depression requires careful haematological monitoring. There is a significant risk of neutropenia, thrombocytopenia, and anaemia occurring less frequently. The nadir is reached between 10-14 days after administration. Blood values usually return to normal within 21&nbsp;&nbsp; days after administration. Doxorubicin therapy should not be started or continued when polynuclear granulocyte counts are below 2000/mm3. In the treatment of acute leukaemias this limit may be set lower, depending on the circumstances.</p><p>&nbsp;</p><p>Severe myelosuppression may result in haemorrhage or superinfection and is an indication for the reduction or suspension of doxorubicin treatment.</p><p>&nbsp;</p><p>Because of the potential for immunosuppression, measures should be taken to prevent secondary infection.</p><p>&nbsp;</p><p>Hyperuricaemia:</p><p>As with other cancer chemotherapeutic agents, there is a risk of hyperuricaemia resulting in acute gout or urate nephropathy following tumor lysis with regimens containing doxorubicin.</p><p>&nbsp;</p><p>Secondary oral neoplasms</p><p>Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to liposomal doxorubicin or those receiving a cumulative liposomal doxorubicin dose greater than 720 mg/m2. Cases of secondary oral cancer were diagnosed both, during treatment with liposomal doxorubicin, and up to 6 years after the last dose. Although the incidence is not known for doxorubicin, patients should be examined at regular intervals for the presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer.</p><p>&nbsp;</p><p>Hepatic impairment:</p><p>Since doxorubicin is excreted mainly via the liver, reduced hepatic function or failure may delay elimination and increase overall toxicity. Therefore it is recommended that hepatic function tests (SGOT, SGPT, alkalic phosphatase and bilirubin) be carried out prior to and during the treatment.</p><p>&nbsp;</p><p>The blood uric acid level should be monitored; sufficient fluid intake should be ascertained (with a daily minimum of 3 l/m&sup2;). If necessary, a xanthine-oxidase inhibitor (allopurinol) may be administered.</p><p>&nbsp;</p><p>Men as well as women should take effective contraceptive measures during and for at least three months after doxorubicin therapy.</p><p>&nbsp;</p><p>Discoloration of urine:</p><p>Patients should be warned that doxorubicin may impart a red colour to the urine, particularly in the first specimen following administration, but that this is no cause for alarm.</p><p>&nbsp;</p><p>Intravesical route:</p><p>The intravesical route of administration should not be attempted in patients with, invasive tumours that have penetrated the bladder wall, urinary tract infections, inflammatory conditions of the bladder.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution should be exercised when administering doxorubicin after or together with other cardiotoxic or anticancer (especially myelotoxic) agents as cardiotoxicity is enhanced.</p><p>&nbsp;</p><p>Doxorubicin peak levels, terminal half-life and volume of distribution may be increased following the co-administration of verapamil.</p><p>&nbsp;</p><p>Doxorubicin may cause exacerbations of hemorragic cystitis caused by previous cyclophosphamide therapy.</p><p>&nbsp;</p><p>As doxorubicin is rapidly metabolised and predominantly eliminated by the biliary system, the concomitant administration of known hepatotoxic chemotherapeutic agents (e.g. methotrexate) could potentially increase the toxicity of doxorubicin as a result of reduced hepatic clearance of the drug.</p><p>&nbsp;</p><p>High dose Cyclosporin and Doxorubicin increases the serum levels of both. This may cause an increase myelotoxicity and excessive immunsuppression.</p><p>&nbsp;</p><p>Inhibitors of cytochrome P-450 (e.g. cimetidine and ranitidine) may decrease the metabolism of doxorubicin, with a possible increase in toxic effects. Inducers of enzyme cytochrome P-450 (e.g. rifampicin and barbiturates) may stimulate the metabolism of doxorubicin, with a possible decrease in efficacy.</p><p>&nbsp;</p><p>Doxorubicin potentiates the effect of radiation therapy and can, even if administered some considerable time after discontinuation of the radiation therapy, cause severe symptoms in the area concerned.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reproductive studies in animals, showed that doxorubicin was teratogenic and embryotoxic (see section 5.3). Doxorubicin is secreted into breast milk. Doxorubicin should not be used during pregnancy or breastfeeding (see section 4.3.).</p><p>&nbsp;</p><p>Doxorubicin is excreted in breast milk. Usage during lactation is therefore not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who suffer from any effects that may impair driving performance (drowsiness, nausea or vomiting) should avoid driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Frequencies are defined using the following convention: Very common (&sup3;1/10); common (&sup3;1/100 to</p><p><strong><em>&lt;1/10); uncommon (</em></strong><em>&sup3;<strong>1/1,000 to &lt;1/100); rare (</strong></em><em>&sup3;<strong>1/10,000 to </strong></em><em>&pound;<strong>1/1,000); very rare (</strong></em><em>&pound;<strong>1/10,000), not known (cannot be estimated from the available data).</strong></em></p><p>&nbsp;</p><p>ADR are very common. Dose limiting toxicities of therapy are myelosuppression and cardiotoxicity which occur in up to &gt;10% and 1-10% of patients respectively.</p><p>&nbsp;</p><p>Doxorubicin may potentiate the toxicity of radiotherapy and other anticarcinogenic therapies (streptozocin, methotrexate, cyclophosphamide).</p><p>&nbsp;</p><p>Neoplasms benign and malignant (including cysts and polys):</p><p><em>Uncommon: </em>Paediatric patients may be at increased risk of later neoplastic disease, particularly acute myeloid leukaemia (AML).</p><p><em>Rare: </em>The occurrence of secondary acute myeloid leukaemia, with or without a preleukaemic phase, has been reported rarely in patients treated with doxorubicin in association with DNA-damaging anti- neoplastic agents. Such cases may also have a short (1-3 year) latency period.</p><p>&nbsp;</p><p>Blood and lymphatic system disorders</p><p><em>Very common:</em></p><p>Myelosuppression includes a transient leukopenia, anemia and thrombocytopenia, reaching its nadir at 10-14 days after treatment.</p><p>&nbsp;</p><p>Endocrine disorders <em>Not&nbsp; known </em><u>Pediatric patients</u></p><p><u>In general intensive chemotherapy regimes can result in pre-pubertal growth failure and endocrine</u></p><p><u>dysfunction. Doxorubicin can contribute to pre-pubertal growth failure. Doxorubicin has reportedly no apparent endocrine late effects</u></p><p>&nbsp;</p><p>Metabolism and nutrition disorders <em>Common - very common </em>Hyperuricaemia</p><p>&nbsp;</p><p>Eye disorders</p><p><em>Rare</em></p><p>Conjunctivitis, lacrimation.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Cardiac disorders</p><p><em>Common-very common</em></p><p>Cardiotoxicity may occur as arrhythmia directly following drug administration; ECG changes, including T-wave flattening and S-T depression, may last up to two weeks after administration. Pericarditis and myocarditis may occur.</p><p>&nbsp;</p><p>The risk of a developing cardiomyopathy gradually increases with an increasing dosage. A cumulative dose of 450-550 mg/m&sup2; should not be exceeded, but irreversible congestive heart failure may even occur with dose of 240 mg/m&sup2;.</p><p>&nbsp;</p><p>Age over 70 or below 15 years should be regarded as a risk factor. Also, concomitant or previous treatment with mitomycin C, cyclophosphamide or dacarbazine has been reported to potentiate doxorubicin induced cardiomyopathy (see section 4.4.).</p><p>&nbsp;</p><p>Cardiotoxicity may be delayed several weeks, months or even years after discontinuation of doxorubicin therapy. The risk of developing heart failure in cancer patients treated with doxorubicin persists throughout life.</p><p>&nbsp;</p><p>Vascular disorders V<em>ery rare</em></p><p>Thrombophlebitis has been reported.</p><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders</p><p><em>Very rare</em></p><p>Some singular cases of pulmonary toxicity have been reported (tachypnoe, dyspnoe/pleural effusion, bronchiolitis obliterans organizing pneumonia, bronchocentric granulomatosis/life-threatening respiratory depression, postpneumonectomy-like syndrome, interstitial pneumonits, radiation pneumonitis, pulmonary embolism). In cases of combined cytostatic treatment (esp. gemcitabine, bleomycin, taxane or rituximab combinations) with or without mediastinal radiotherapy as well as in predisposed patients the possibility of occurrence of pulmonary toxicity should be considered.</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p><em>Very common:</em></p><p>Nausea, vomiting, mucositis (as stomatitis and proctitis) and diarrhoea may occur 5 to 10 days after administration. Damage of the gastro-intestinal tract can lead to ulceration, haemorrhage and perforation.</p><p>&nbsp;</p><p>Mucositis commonly begins with a burning sensation in the mouth and throat 5-10 days after treatment and may progress to ulceration with the associated risk of secondary infection. Mucositis may also affect the vagina, rectum and oesophagus.</p><p>&nbsp;</p><p>Hepatobiliary disorders:</p><p><em>Common</em></p><p>Slight transient increases of liver enzymes have been reported. Concomitant irradiation of the liver may cause severe hepatotoxicity, sometimes progressing to cirrhosis.</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p><em>Very common:</em></p><p>Reversible alopecia in the majority of patients, hyperpigmentation of nailbeds, dermal creases, onycholysis. Doxorubicin is highly irritant and extravasation at the infusion site may cause local pain, irritation, inflammation, thrombophlebitis, even leading to serious ulceration and skin necrosis.</p><p>Hypersensitivity reactions such as cutaneous reactions (rashes, pruritus, urticaria, angiooedema, fever and anaphylaxis) have been occasionally reported.</p><p>Doxorubicin influences and potentiates normal tissue reactions to radiation. Also, late (&quot;recall&quot;) reactions may occur when doxorubicin is administered some time after irradiation.</p><p><em>Not known:</em></p><p>palmar-plantar erythrodysesthesia</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p><em>Common:</em></p><p>Intravesical administration may cause the following adverse reactions: hematuria, vesical and urethral irritation, stranguria and polyuria. These reactions are usually of moderate severity and of short duration. Intravesical administration of doxorubicin may sometimes cause hemorrhagic cystitis; this may cause a decrease in bladder capacity. Doxorubicin causes red discoloration of the urine.</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p>&nbsp;</p><p><em>Rare:</em></p><p>conjunctivitis, lacrimation.</p><p>Facial flushing may occur if the injection is given too rapidly. Thrombophlebitis and conjunctivitis have been reported.</p><p>&nbsp;</p><p><u>Post-Marketing Experience</u></p><p>&nbsp;</p><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p><p><em>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Secondary oral neoplasms (see section 4.4)</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The symptoms of an overdose are likely to be an exaggeration<strong><em>/</em></strong>extension of the pharmacological action. Fatalities due to single doses of 250 mg and 500 mg doxorubicin have been reported. Acute myocardial degeneration may occur within 24 hours. Severe myelosuppression may occur with peak effects 10 to 15 days after administration of doxorubicin. Cardiac failure may occur up to six months following an overdose.</p><p>Symptomatic supportive measures should be adopted in cases of overdosage.</p><p>&nbsp;</p><p>As soon as possible the appropriate measures should be taken, such as the administration of heart glycosides and diuretics.</p><p><strong><em>&nbsp;</em></strong></p><p>Treatment of possible haemorrhage and of infections due to severe myelo- or immuno-suppression may be necessary. Blood transfusions and reverse barrier nursing may be required.</p><p>&nbsp;</p><p>Haemodialysis is of no benefit as doxorubicin is mostly excreted in the biliary tract and by the intestine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC classification: L01D B01</p><p>&nbsp;</p><p>Doxorubicin has been shown to have antineoplastic activity in several animal models and is effective in humans but there is as yet no consensus as to how doxorubicin and other anthracyclines exert their anti tumour activity. Three principal biochemical mechanisms have been proposed: DNA intercalation, membrane binding and metabolic activation via reduction.</p><p>&nbsp;</p><p>An important cause of treatment failure with doxorubicin and other anthracyclines is the development of resistance. In an attempt to overcome cellular resistance to doxorubicin the use of calcium antagonists such as verapamil has been considered since the primary target is the cell membrane; verapamil inhibits the slow channel of calcium transport and can enhance cellular uptake of doxorubicin. <em>Chang et al, 1989 </em>have shown that the cytotoxicity of doxorubicin is potentiated by verapamil <em>in vitro </em>using three pancreatic cancer cell lines.</p><p>&nbsp;</p><p>They also investigated a possible role of its major reduction metabolite, doxorubicinol, which occurs in human plasma, but concluded that it was not involved in the intracellular accumulation/retention of doxorubicin. It should be noted that a combination of doxorubicin and verapamil has been shown to be associated with severe toxic effects in animal experiments. (<em>Sridhar et al, 1992</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The intravenous administration of doxorubicin is followed by a rapid plasma clearance (t&frac12; = 10 min.) and significant tissue binding. The terminal half-life is approximately 30 hours.</p><p>Doxorubicin is partly metabolised, mainly to doxorubicinol and to a lesser extent, to the aglycon, and is conjugated to the glucuronide and sulfate. Biliary and fecal excretion represents the major excretion route. About 10 % of the dose is eliminated by renal excretion. Plasma protein binding of doxorubicin ranges from 50-85 %. The volume of distribution is 800-3500 L/m&sup2;.</p><p>Doxorubicin is not absorbed after oral administration; it does not cross the blood-brain barrier. Impairment of liver function may decrease the clearance of doxorubicin and its metabolites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The LD50 after a single intravenous bolus injection of doxorubicin to rats, mice and rabbits were 12.6,</p><p>9.4 and 6 mg/kg, respectively.</p><p>&nbsp;</p><p>Reduction in body weights and survival times were seen in old and young rats administered a single intravenous dose of 2.5 and 5 mg/kg, respectively.</p><p>&nbsp;</p><p>The animal data show an increased toxicity in elder rats.</p><p>&nbsp;</p><p>As expected from its interaction with DNA and cytotoxic properties doxorubicin is mutagenic, showing chromosome damage <em>in vitro </em>in human lymphocytes and is also carcinogenic in animals. The compound is also teratogenic and embryocidal. Although i.v. and i.p. dosage to mice and rats at doses up to 1mg/kg from days 7 to 13 of gestation produced no evidence of teratogenicity a higher dose of 2mg/kg i.p. for longer to rats caused atresia of the oesophagus and intestine and cardiovascular abnormalities. In rabbits dosed i.v. at up to 0.6mg/kg on days 16-18 abortions occurred but there were no foetal abnormalities. Post-natal renal damage was produced in rats dosed with 1 or 1.5mg/kg of doxorubicin during days 6-9 or 10-12.</p><p>&nbsp;</p><p>Microscopic examination of the heart of patients shows evidence of a severe cardiomyopathy and a variety of alterations have been described the majority of which have been reproduced in animal models in the mouse, rat, rabbit, dog and monkey; the development and character of the lesions in the rat and rabbit closely resemble those in humans although rats develop cardiomyopathy at lower total doses than rabbits. The pathogenesis is difficult to assess since a large number of complex biochemical effects have been shown to occur in the heart.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydrochloric acid (for ph adjustment), sodium chloride, water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contact with any solution of an alkaline pH should be avoided as it will result in hydrolysis of the drug. Doxorubicin should not be mixed with heparin and 5-fluororuacil as a precipitate may form and it is not recommended that doxorubicin be mixed with other drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medicinal product as packaged for sale: 2 years. Remove solution from vial immediately before use.
 
Shelf life after dilution: Chemical and physical in-use stability has been demonstrated up to 24 hours at 2-8°C.
In use: From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8&deg;C).</p><p>Storage of the medicinal product at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15&deg; to 25&deg;C).</p><p>Keep the vial in the outer carton in order to protect from light. For storage of the diluted product, see sec</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vials of Ph.Eur. Type I clear glass with grey teflon-coated chlorobutyl rubber stopper and aluminium crimp cap, packed in a carton.</p><p>&nbsp;</p><p>Package sizes:</p><p>5 ml Vial: 10 mg doxorubicin hydrochloride. 25 ml Vial: 50 mg doxorubicin hydrochloride. 50 ml Vial: 100 mg doxorubicin hydrochloride.</p><p>100 ml Vial: 200 mg doxorubicin hydrochloride<strong><em>. </em></strong>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only.</p><p>&nbsp;</p><p>Observe guidelines for handling cytotoxic drugs.</p><p>&nbsp;</p><p>The following protective recommendations are given due to the toxic nature of this substance:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel should be trained in good technique for handling.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant staff should be excluded from working with this drug.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel handling doxorubicin should wear protective clothing: goggles, gowns and disposable gloves and masks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All items used for administration or cleaning, including gloves, should be placed in high risk waste disposal bags for high temperature (700&deg;C) incineration.</p><p>&nbsp;</p><p>Accidental contact with the skin or eyes should be treated immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution: medical attention should be sought.</p><p>&nbsp;</p><p>Spillage or leakage should be treated with dilute sodium hypochlorite (1% available chlorite) solution, preferably soaking overnight and then rinse with water.</p><p>&nbsp;</p><p>All cleaning materials should be disposed of as indicated previously.</p><p>&nbsp;</p><p>Recommended infusion solutions are Sodium Chloride Intravenous Infusion 0.9% w/v, Glucose Intravenous Infusion 5% w/v or Sodium Chloride and Glucose Intravenous Infusion (see section 4.2.).</p><p>&nbsp;</p><p>Because of the various existing dosage schemes the use is only recommended under the direction of those experienced in cytotoxic therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ebewe Pharma Ges.m.b.H.Nfg.KG,  A-4866 Unterach, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>